Read articles from Global

May 13, 2026 by substack.com

Debates around tobacco harm reduction are increasingly exposing tensions between public health messaging and institutional behaviour. Critics argue that some organisations continue to reject lower-risk nicotine alternatives while simultaneously supporting policies that have failed to reduce smoking effectively. The discussion highlights what is seen as a growing disconnect between scientific evidence, consumer experiences and regulatory narratives. Concerns are also raised about selective framing of risk, particularly when safer alternatives are treated similarly to combustible cigarettes. At the centre of the debate lies a broader question of consistency, credibility and whether public health policies are being applied evenly across different forms of nicotine use.

May 13, 2026 by filtermag.org

Psilocybin, a compound in "magic mushrooms," shows promise in treating substance use disorders, with a recent study finding it more effective in smoking cessation than nicotine patches when combined with therapy. The study had limitations in participant diversity, excluding those with certain mental health conditions. Researchers suggest further exploring psychedelics for addiction treatment, emphasizing the need for inclusive trials. The six-month follow-up showed a higher abstinence rate in the psilocybin group. Future research should include diverse populations for better representation. The study's use of nicotine patches raised questions due to their low efficacy compared to newer options like vapes, urging for more relevant comparators in future studies.

May 11, 2026 by gfn.tv

Today we explore the rise of harm reduction across the Middle East and North Africa through the story of MENAHRA and the activists, healthcare workers, and organizations fighting stigma, HIV, and outdated drug policies. In regions where addiction and public health issues are often heavily stigmatized, harm reduction became more than healthcare — it became a movement for human rights and survival.

May 11, 2026 by bbc.com

World Health Organisation reports smoking claims 7 million lives yearly. Smokers turn to vaping for health reasons, but WHO warns of 100 million e-cigarette users globally, fueling nicotine addiction. Recent study links vaping to cancer, raising concerns if it's as harmful as smoking. Expert opinion from Professor Lion Shahab questions vaping's safety compared to smoking.

May 08, 2026 by substack.com

This is a long article; a comment on the FDA’s Draft Guidance for Industry: Flavored ENDS Premarket Applications – Considerations Related to Youth Risk. Comment by: Clive Bates, Stefanie Miller, Brad Rodu, Sally Satel, and David Sweanor. The Draft Guidance regulating safer alternatives to smoking, including flavored ENDS, directly impacts the health and well-being of more than 60 million Americans, most of whom are adults. Despite its importance, the guidance is considered disconnected from real-world conditions and unfit for its intended purpose. The public health standard “Appropriate for the Protection of Public Health” (APPH) should take into account actual market conditions, real human behavior, and the likely public health consequences of authorization decisions.

May 08, 2026 by news-medical.net

Public perceptions of e-cigarettes' risks have shifted due to factors like the EVALI scare. Although e-cigarettes were initially seen as less harmful than cigarettes, negative views have increased. A study analyzed data from a clinical trial of smokers using e-cigarettes, finding that perceptions of e-cigarette risk rose after EVALI. Even though e-cigarettes are generally considered less harmful, EVALI led to a temporary increase in perceived risk. The study suggests monitoring smokers' perceptions of e-cigarettes to guide future policies. Correcting misperceptions is vital to encourage smokers to transition to less harmful options. Recommendations include FDA-approved aids for smoking cessation over e-cigarettes.

May 08, 2026 by filtermag.org

Around 41 million people globally live with HIV, with smoking rates among this group being significantly higher than national averages. In countries like Australia, Austria, Germany, and Italy, up to half of people with HIV smoke. The National Cancer Institute notes that smoking cessation is crucial for those with HIV, as it can impact life expectancy and increase the risk of smoking-related diseases. Interventions to quit smoking should be integrated into HIV care services, as seen in countries like Switzerland and the United States. Safer nicotine products may play a vital role in helping people with HIV quit smoking and improve their overall health outcomes.

May 08, 2026 by cbsnews.com

FDA approved fruit-flavored e-cigarettes for adult smokers, marking a policy change following lobbying efforts on President Trump.

May 06, 2026 by thefirebreak.org

The influence of private funding on global public health policy is becoming an increasingly debated issue. Analysis highlights how large-scale philanthropic investment can shape not only funding priorities but also the direction of international health strategies. In the case of Michael Bloomberg, billions of dollars have been channelled into tobacco control initiatives through a network of interconnected organisations. This structure is argued to amplify a single policy perspective across multiple institutions, including programmes linked to the World Health Organization. Critics suggest that such influence may limit debate around harm reduction approaches and alternative nicotine products. The discussion raises broader questions about transparency, accountability and the role of private actors in shaping global health agendas.

May 06, 2026 by tobaccojournal.com

The debate around tobacco policy is increasingly shifting from harm reduction towards a more precautionary, protection-focused approach. While harm reduction strategies aim to lower risks for existing smokers, critics argue that newer policies place greater emphasis on preventing any nicotine use altogether. This shift reflects growing concern about addiction, youth uptake and the long-term societal impact of nicotine products. At the same time, it raises questions about whether moving away from harm reduction could limit options for smokers who are unable or unwilling to quit entirely. The discussion highlights a widening divide between approaches centred on individual risk reduction and those prioritising population-level prevention. Ultimately, the issue underscores the challenge of balancing public health protection with pragmatic strategies to reduce smoking-related harm.